Focused on the patient - Baylor Health Care System

38<strong>Focused</strong> on innovationOncology Publications in 20071. Batts ED, Maisel C, Kane D, Liu L, Fu P, O’Brien T, Remick S, Bahlis N,Gerson SL. O6-benzylguanine and BCNU in multiple myeloma: a phase IItrial. Cancer Chemother Pharmacol 2007;60(3):415–421.2. Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, IlegboduD, Asmar L, O’Shaughnessy JA. Phase II trial of capecitabine and weeklypaclitaxel in patients with metastatic breast cancer previously treatedwith every-3-week taxane therapy. Clin Breast Cancer 2007;7(6):465–470.3. Boland CR. Clinical uses of microsatellite instability testing in colorectalcancer: an ongoing challenge. J Clin Oncol 2007;25(7):754–756.4. Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis ofmicrosatellite instability and abnormal immunohistochemistry and clinicalbehavior in Lynch syndrome: from bench to bedside. Fam Cancer 2007Jul 17 [Epub ahead of print].5. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE,Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L,Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D,Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, CastiglioneM, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, CarpentieriM, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup ExemestaneStudy. Survival and safety of exemestane versus tamoxifen after2-3 years’ tamoxifen treatment: a randomised controlled trial. Lancet2007;369(9561):559–570.6. Dao TN, Lamont JP, Knox SM. Clinical utility of breast magnetic resonanceimaging in patients presenting with primary breast cancer. Proc(Bayl Univ Med Cent) 2007;20(3):227–230.7. Eager R, Harle L, Nemunaitis JJ. Lung cancer vaccines. Curr Gene Ther2007;7(6):469–484.8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, NegrierS, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, HutsonTE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, BukowskiRM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cellcarcinoma. N Engl J Med 2007;356(2):125–134.9. Ewer MS, O’Shaughnessy JA. Cardiac toxicity of trastuzumab-relatedregimens in HER2-overexpressing breast cancer. Clin Breast Cancer2007;7(8):600–607.10. Fini L, Hotchkiss E, Fogliano V, Graziani G, Romano M, De Vol EB, QinH, Selgrad M, Boland CR, Ricciardiello L. Chemopreventive propertiesof pinoresinol-rich olive oil involve a selective activation of the ATM-p53cascade in colon cancer cell lines. Carcinogenesis 2007 Nov 13 [Epubahead of print].11. Fini L, Selgrad M, Fogliano V, Graziani G, Romano M, Hotchkiss E,Daoud YA, De Vol EB, Boland CR, Ricciardiello L. Annurca applepolyphenols have potent demethylating activity and can reactivatesilenced tumor suppressor genes in colorectal cancer cells. J Nutr2007;137(12):2622–2628.12. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, SuZZ, Grant S, Dent P, Curiel DT, Senzer N, Nemunaitis J. Melanomadifferentiation associated gene-7/interleukin-24 (mda-7/IL-24): novelgene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol2007;224(3):300–307.13. George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R,Bukowski RM. Phase I trial of PEG-interferon and recombinant IL-2 inpatients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol2007 [Epub ahead of print].14. Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML,Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, PulsipherMA, Chauncey TR, Mielcarek M, Storer BE, Storb R. Nonmyeloablativeunrelated donor hematopoietic cell transplantation to treat patients withpoor-risk, relapsed, or refractory multiple myeloma. Biol Blood MarrowTransplant 2007;13(4):423–432.15. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D,Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. TheCpG island methylator phenotype and chromosomal instability areinversely correlated in sporadic colorectal cancer. Gastroenterology2007;132(1):127–138.16. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, BlankeCD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK,Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: aparadigm for the management of metastatic colorectal cancer. Oncologist2007;12(1):38–50.17. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, ValeroV, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, HessKR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determinationof oestrogen-receptor status and ERBB2 status of breast carcinoma: agene-expression profiling study. Lancet Oncol 2007;8(3):203–211.18. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube7 S, SomerfieldMR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. AmericanSociety of Clinical Oncology 2007 update of recommendations forthe use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287–5312.19. Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cellcarcinoma: a phase III overview. Expert Rev Anticancer Ther2007;7(9):1193–1202.20. Hutson TE. Targeted therapy for renal cell carcinoma: a new treatmentparadigm. Proc (Bayl Univ Med Cent) 2007;20(3):244–248.21. Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cellcarcinoma. Oncology (Williston Park) 2007;21(10):1175–1180.22. Hutson TE, Figlin RA. Renal cell cancer. Cancer J 2007;13(5):282–286.23. Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling fordiagnosis and prognosis of human cancer. DNA Cell Biol 2007;26(5):293–300.24. Jones SE, Cantrell J, Vukelja S, Pippen J, O’Shaughnessy J, Blum JL,Brooks R, Hartung NL, Negron AG, Richards DA, Rivera R, Holmes FA,Chittoor S, Whittaker TL, Bordelon JH, Ketchel SJ, Davis JC, IlegboduD, Kochis J, Asmar L. Comparison of menopausal symptoms during thefirst year of adjuvant therapy with either exemestane or tamoxifen in earlybreast cancer: report of a Tamoxifen Exemestane Adjuvant Multicentertrial substudy. J Clin Oncol 2007;25(30):4765–4771.25. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG,Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B,Langston A, Pulsipher MA, McSweeney PA, Wade JC, Epner E, Bo PetersenF, Bethge WA, Maloney DG, Storb R. Relapse risk in patients withmalignant diseases given allogeneic hematopoietic cell transplantationafter nonmyeloablative conditioning. Blood 2007;110(7):2744–2748.26. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS,Mok SC. Effect of a c-Met-specific, ATP-competitive small-moleculeinhibitor SU11274 on human ovarian carcinoma cell growth, motility, andinvasion. Int J Gynecol Cancer 2007 Nov 16 [Epub ahead of print].27. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D,Conrad C, Fink KL, Robins HI, Mehta M, Deangelis L, Raizer J, Hess K,Lamborn KR, Dancey J, Prados MD; for the North American Brain TumorConsortium and the National Cancer Institute. Pharmacokinetic and tumordistribution characteristics of temsirolimus in patients with recurrent malignantglioma. Clin Cancer Res 2007;13(24):7401–7406.28. Kuhn JA, Nochumson J. Operative probe scintimetry with indium andtechnetium for colorectal cancer. J Surg Oncol 2007;96(4):290–296.29. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR,Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, ParkES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, DePass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, DentP, Senzer N, Nemunaitis JJ, Fisher PB. mda-7/IL-24, novel anticancercytokine: focus on bystander antitumor, radiosensitization and antiangiogenicproperties and overview of the phase I clinical experience. Int JOncol 2007;31(5):985–1007.